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Abstract
Background:	Vitamin	K	antagonists	(VKA)	are	used	for	the	treatment	of	thromboem-
bolism.	Patients	with	severe	VKA-	associated	bleeding	require	immediate	restoration	
of	 haemostasis.	 Clinical	 studies	 on	 the	 effect	 of	 prothrombin	 complex	 concentrate	
(PCC)	are	heterogeneous	with	respect	to	outcome	of	bleeding.
Objective:	To	evaluate	 the	clinical	outcome	of	patients	 treated	with	PCC	for	VKA-	
associated	bleeding.
Methods:	We	performed	a	cohort	study	of	consecutive	patients	who	received	PCC	for	
VKA-	related	bleeding	in	five	Dutch	hospitals.	Data	were	collected	by	chart	review	on	
the	bleeding	event,	international	normalized	ratio	(INR),	haemostatic	efficacy,	throm-
boembolic	(TE)	complications,	and	mortality.	The	primary	outcome	was	effective	hae-
mostasis,	assessed	by	an	adaptation	of	the	Sarode	criteria	with	a	surrogate	outcome	
for	patients	with	ICH	without	repeat	CT.
Results:	One	hundred	patients	were	included.	Mean	age	was	74	years,	54%	were	male	
and	79%	received	VKA	for	atrial	fibrillation.	Most	patients	presented	with	ICH	(41%)	
or	GI	 bleeding	 (36%).	 Effective	 haemostasis	was	 achieved	 in	 67/98	 (68%)	 patients	
using	the	adapted	classification.	Surrogate	outcomes	were	applied	for	32	patients	and	
data	for	two	patients	was	missing.	Median	pre-	treatment	INR	was	3.9	(IQR	2.9-	5.8).	
One	hour	after	PCC	infusion,	the	INR	was	available	for	50	patients	and	of	these,	35	
(70%)	had	an	INR	≤1.4.	TE	complications	occurred	in	five	patients	and	22	died	(60%	
bleeding-	related)	within	30	days.
Conclusion:	PCC	achieved	effective	haemostasis	 in	68%	of	evaluable	patients	with	
VKA-	associated	bleeding.	TE	complication	rates	were	 low,	but	mortality	 rates	were	
high,	due	to	the	large	number	of	patients	with	ICH.
K E Y W O R D S
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1  | INTRODUCTION
Vitamin	K	antagonists	(VKA)	are	frequently	prescribed	oral	anticoagu-
lants	and	are	effective	in	the	treatment	and	prevention	of	venous	and	
arterial thromboembolic diseases.1	An	important	complication	of	VKA	
treatment	is	the	occurrence	of	bleeding	events,	which	typically	involve	
the	gastrointestinal	system,	central	nervous	system,	or	soft	 tissues.2 
The	annual	incidence	rate	of	major	bleeding	episodes	in	VKA	treated	
patients	is	1-	3%.3–6	Life-	threatening	bleeding	occurs	in	approximately	
0.25%	of	patients	annually.4
Patients	 with	 severe	 VKA-	associated	 bleeding	 require	 immedi-
ate	 restoration	of	 haemostasis	 by	 reversing	 the	 anticoagulant	 effect	
of	VKA	as	part	of	the	bleeding	management.1	The	first	step	in	rever-
sal	 is	 usually	vitamin	K	 administration.7,8	 Intravenously	 administered	
vitamin	K	 normalizes	 the	 international	 normalized	 ratio	 (INR)	within	
12-	16	hours,9	whereas	oral	administration	of	vitamin	K	will	take	up	to	
24	hours	to	take	effect.10	Since	immediate	reversal	is	indicated	in	these	
patients,	several	international	treatment	guidelines	recommend	the	use	
of	 prothrombin	 complex	 concentrate	 (PCC).1,11,12	 Three-	factor	 PCC	
contains	the	vitamin	K-	dependant	coagulation	factors	II,	IX,	and	X,	and	
protein	C	and	S.	Four-	factor	prothrombin	complex	concentrate	(PCC)	
additionally	contains	factor	VII.13,14	PCC	products	are	highly	effective	
in	normalizing	INR.3,15	Advantages	of	PCC	over	substitution	with	fresh	
frozen	plasma	(FFP)	are	a	smaller	volume	and	shorter	duration	of	infu-
sion	and	a	low	pathogen	transmission	risk.16	In	the	Netherlands,	PCC	
has	been	widely	available	for	decades	in	all	national	hospitals	and	there	
is	ample	experience	with	its	use	in	patients	with	bleeding	or	in	those	
that	need	to	undergo	emergency	invasive	procedures.
In	2013,	a	new	standard	was	introduced	to	evaluate	haemostatic	
efficacy	of	reversal	agents	in	bleeding	complications	related	to	antico-
agulant	use.17	This	classification	scheme	was	developed	in	collabora-
tion	with	the	Food	and	Drug	Administration	(FDA)	for	a	randomized	
controlled	trial	(RCT)	comparing	Beriplex	(PCC)	with	FFP.17	In	the	cur-
rent	 studies	 testing	 antidotes	 for	 the	 direct	 oral	 anticoagulants,18,19 
this	 classification	 scheme	 is	 standardly	 used	 to	 assess	 haemostatic	
efficacy	 of	 the	 reversal	 agent.	 Both	 the	 FDA	 and	 the	 European	
Medicines	 Agency	 (EMA)	 have	 accepted	 this	 standard	 for	 ongoing	
and	future	studies.	This	endpoint	was	not	used	previously	in	studies	
of	 reversing	VKA	 in	 the	setting	of	haemorrhage.	Therefore,	 the	cur-
rent	study	addressed	this	endpoint	in	order	to	provide	comparison	to	
the	results	of	ongoing	studies	of	antidotes	to	DOACs.	The	aim	of	this	
cohort	study	was	to	evaluate	clinical	outcome	parameters,	 including	
haemostatic	efficacy,	thromboembolic	complications,	and	mortality	in	
patients	treated	with	PCC	for	VKA-	associated	bleeding	complications.
2  | METHODS
2.1 | Study design and study population
We	performed	a	retrospective	cohort	study	of	consecutive	patients	
who	received	PCC	for	a	VKA-	associated	bleeding	between	September	
2014	and	December	2015	 in	 five	Dutch	 tertiary	university	medical	
centers	(Amsterdam,	Maastricht,	Rotterdam,	Leiden,	and	Groningen).	
Every	participating	hospital	included	20	patients.	The	study	was	per-
formed	in	accordance	with	local	ethics	regulations,	and	the	Institutional	
Review	Board	of	 the	Academic	Medical	Center,	Amsterdam	waived	
the	need	for	a	formal	review	of	this	study.	Informed	consent	was	not	
obtained	from	the	patients,	because	all	data	was	retrospectively	and	
anonymously	collected	from	medical	charts	and	discharge	letters.
Patients	18	years	or	older	receiving	PCC	therapy	for	a	VKA-	related	
acute	bleeding	event	were	eligible	 for	 inclusion.	Each	of	 the	partici-
pating	hospitals	started	the	retrospective	data	collection	at	a	different	
time	point,	and	data	were	collected	consecutively	for	the	first	20	pa-
tients	that	received	PCC	in	the	prior	4-	6	months.	Patients	were	iden-
tified	through	PCC	distribution	lists	and	administration	files	from	the	
hospital	blood	bank	or	pharmacy.	Data	were	collected	on	medical	his-
tory,	concomitant	medication,	VKA-	related	bleeding	event,	PCC	treat-
ment,	other	procedures	and	interventions	to	treat	the	bleeding,	INR,	
haemostatic	efficacy,	thromboembolic	(TE)	complications,	and	mortal-
ity.	All	information	was	recorded	in	standardized	case	report	forms.
Patients	all	received	4-	factor	PCC	(Cofact;	Sanquin	Blood	Supply,	
Amsterdam,	 the	 Netherlands)	 according	 to	 local	 hospital	 protocol.	
Each	mL	of	PCC	contains	14	IU	factor	II,	7	IU	factor	VII,	25	IU	factor	
IX,	14	IU	factor	X,	11	IU	protein	C,	and	1	IU	protein	S.	PCC	was	ad-
ministered	intravenously	and	the	dose	was	dependent	on	INR	at	pre-
sentation	and	body	weight.	The	speed	of	administration	was	variable	
and	not	recorded	for	study	purposes.	In	Dutch	clinical	practice,	FFP	is	
not	considered	to	be	a	VKA	reversal	method.	Hence,	if	a	VKA-	related	
bleeding	was	severe	enough,	PCC	was	administered.
2.2 | Outcome parameters
2.2.1 | Haemostatic efficacy
The	primary	outcome	parameter	was	haemostatic	 efficacy	 of	PCC	at	
24	hours	after	the	start	of	 infusion,	assessed	by	a	modification	of	the	
Sarode	 et	al.	 criteria,17	 based	 on	Dutch	 clinical	 practice.	 Haemostatic	
efficacy	was	classified	as	excellent,	good,	or	poor	 for	different	bleed-
ing	 localizations	 based	 on	 haemoglobin	 decrease	 over	 24	hours	
Essentials
•	 Data	on	clinical	outcome	of	vitamin	K	antagonist	(VKA)-associated	bleeding	is	scarce.
•	 Cohort	study	of	patients	with	VKA	bleeds	treated	with	prothrombin	complex	concentrate	(PCC).
•	 Effective	haemostasis	was	achieved	in	68%	of	patients	with	a	VKA-associated	bleeding.
•	 Thromboembolism	rates	were	low	and	mortality	rates	high	at	30	days	after	PCC	administration.
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(gastrointestinal	[GI]	bleeding),	hematoma	expansion	(intracranial	haem-
orrhage	[ICH]),	or	cessation	of	visible	blood	loss.17	Effective	haemostasis	
was	defined	as	the	efficacy	ratings	excellent	or	good	(Table	S1).	When	
no	repeat	CT	scanning	was	performed	within	24	hours	due	to	standard	
clinical	 practice	 policy,	 surrogate	 outcome	 categories	 for	 haemostatic	
efficacy	 (“surrogate	efficacy”)	 in	 ICH	patients	were	set.	Patients	were	
first	classified	as	stable	neurological	condition	since	admission,	cessation	
of	 further	medical	 treatment	due	 to	a	poor	neurological	 condition,	or	
no	records	available.	The	category	“stable	neurological	condition	since	
admission”	was	 surrogate	 for	effective	haemostasis,	whereas	 the	cat-
egory	“cessation	of	further	medical	treatment	due	to	a	poor	neurological	
condition”	was	indicative	of	non-	effective	or	poor	haemostasis.	Data	on	
the	Glasgow	Coma	Scale	score,	neurological	signs	and	symptoms,	neu-
rological	examination,	and	clinical	course,	were	used	to	evaluate	these	
patients	on	the	surrogate	outcome	and	were	retrieved	by	chart	review.
The	secondary	analysis	described	the	results	of	the	original	hae-
mostatic	efficacy	classification17	and	the	surrogate	efficacy	outcome	
separately.
2.2.2 | Clinical presentation and course
Bleeding	 events	 were	 classified	 as	 major	 or	 minor	 bleeding.	Major	
bleeding	was	defined	according	to	the	ISTH	criteria	as	clinically	overt	
and	causing	a	decrease	 in	haemoglobin	of	≥2	grams	per	decilitre	or	
requiring	two	or	more	units	of	packed	cells	or	whole	blood,	occurring	
in	 a	 critical	 organ	or	 site,	 or	 being	 fatal.20	 All	 other	 bleedings	were	
considered	minor	bleedings.
All	major	bleeding	events	were	classified	using	two	classification	
schemes	that	were	developed	and	published	previously.21–23	The	first	
classification	was	used	 to	 assess	 the	 severity	of	 the	major	 bleeding	
event	at	presentation	(Table	S2A).	The	second	classification	was	used	
to	assess	the	applied	procedures	and	interventions	for	treatment	and	
the	clinical	outcome	of	the	bleeding	event	(Table	S2B).	Both	classifica-
tion	schemes	consist	of	four	different	categories,	with	one	being	the	
mildest	and	four	the	most	severe.21–23
2.3 | Statistical analysis
Continuous	variables	are	described	by	measures	of	central	tendency	
and	 variability.	 Categorical	 variables	 are	 presented	 as	 proportions	
(n/N)	 and	 percentage	 (%).	 Comparisons	 between	 patients	 from	 the	
different	centers	were	made	using	the	one-	way	analysis	of	variance	
(ANOVA)	 for	 continuous	 variables,	 and	 by	 Chi-	square	 test	 for	 cat-
egorical	 variables.	 A	P-	value	 of	 less	 than	 .05	was	 considered	 to	 be	
statistically	 significant.	All	 statistical	 analyses	were	performed	using	
the	SPSS	package	(version	24.0,	Chicago,	Illinois).
3  | RESULTS
3.1 | Study population
Demographic	 and	 clinical	 characteristics	 of	 the	100	patients	with	 a	
VKA-	associated	bleeding	event	treated	with	PCC	at	presentation	are	
detailed	in	Table	1.	The	mean	age	was	74	±	12	years	and	54	(54%)	of	
the	patients	were	male.	There	were	no	significant	differences	in	age,	
sex,	or	weight	between	the	five	centers.	Almost	three-	quarters	of	the	
study	 population	 had	 a	 history	 of	 hypertension	 (71%)	 and	 approxi-
mately	one-	quarter	had	as	history	of	type	2	diabetes	mellitus	(24%).	
Antiplatelet	drugs	were	used	in	17	(17%)	of	patients;	of	whom	seven	
patients	clopidogrel	and	six	aspirin.
TABLE  1 Demographics	and	characteristics	of	patients	with	a	
VKA-	associated	bleeding	event
Total patients N = 100
Age	in	years,	mean	(SD) 74.4	±	11.6
Male	sex,	n	(%) 54	(54)
Weight	in	kg,	mean	(SD)a
Males 85.0	±	18.0
Females 70.2	±	15.1
Medical	history,	n	(%)
Hypertension 71	(71)
Diabetes mellitus 24	(24)
Cancer 18	(18)
Heart valve disease 16	(16)
Peripheral	vascular	disease 11	(11)
Stroke 10	(10)
Thyroid disease 6	(6)
Medication	use,	n	(%)
Antiplatelet	agents 17	(17)
NSAIDs 9	(9)
Type	of	VKA,	n	(%)
Acenocoumarol 65	(65)
Phenprocoumon 33	(33)
Warfarin 1	(1)
Unknown 1	(1)
Indication	for	VKA	therapy,	n	(%)
Atrial	fibrillation 79	(79)
Venous	thromboembolism 7	(7)
Mechanical	heart	valve 6	(6)
Other 8	(8)
Type	of	bleeding,	n	(%)
Intracranial 41	(41)
Gastrointestinal 36	(36)
Intramuscular/subcutaneous 11	(11)
Retroperitoneal 4	(4)
Epistaxis 4	(4)
Genitourinary 2	(2)
Hemoptysis 2	(2)
NSAIDs,	 non-	steroidal	 anti-	inflammatory	 drugs;	 SD,	 standard	 deviation;	
VKA,	vitamin	K	antagonist.
aData	missing	for	17	males	and	18	females.
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The	most	 frequently	 prescribed	 type	 of	VKA	was	 acenocoumarol	
(65	[65%]).	Of	the	included	patients,	in	79	(79%)	the	indication	for	VKA	
was	atrial	fibrillation,	in	seven	(7%)	venous	thromboembolism	and	in	the	
remainder	mechanical	heart	valves	or	other	conditions.	The	majority	of	
patients	(72	[72%])	were	treated	with	VKA	for	>12	months	at	the	time	
of	bleeding.
A	total	of	86	 (86%)	patients	presented	with	a	major	bleeding	and	14	
(14%)	had	a	minor	bleeding;	41	(41%)	patients	presented	with	an	ICH	and	36	
(36%)	patients	with	a	GI	bleeding.	The	mean	age	of	patients	with	an	ICH	was	
72	±	12	years	and	49%	of	them	were	male.	The	36	patients	with	GI	bleeding	
had	a	mean	age	of	76	±	11	years	and	67%	were	male.	When	combining	the	
other	types	of	bleeding	(n	=	23),	the	mean	age	was	75	±	12	years	and	44%	
were	male.	The	distribution	of	bleeding	types	differed	significantly	between	
the	five	centers	(p = .01);	two	centers	included	predominantly	ICH,	two	in-
cluded	mostly	GI	bleeds,	and	one	included	a	variety	of	bleeding	types.
3.2 | Treatment of VKA- related bleedings
The	median	dose	of	administered	PCC	was	2000	international	units	
(IU)	 for	men	 (median	 25	IU	 per	 kg	 body	weight)	 and	 1500	IU	 for	
women	(median	22	IU	per	kg	body	weight).	Vitamin	K	was	given	to	
79	(79%)	patients	in	addition	and	parallel	to	PCC	treatment.	In	45	
(57%)	of	79	patients,	vitamin	K	was	administered	intravenously	and	
61	(77%)	received	a	dose	of	10	mg	vitamin	K.	Packed	cells	were	ad-
ministered	in	45	(45%),	platelet	transfusions	in	6	(6%),	and	FFP	in	8	
(8%)	of	the	patients.	In	39	(39%)	patients	a	procedure	was	indicated	
to	control	or	stop	the	bleeding;	in	15	(38%)	a	surgical,	in	21	(54%)	
an	endoscopic,	and	in	three	(8%)	a	radiological	procedure	was	per-
formed	(Table	2).
3.3 | Outcome parameters
3.3.1 | Haemostatic efficacy
Assessment	 of	 the	 adapted	 classification	 of	 haemostatic	 efficacy	
showed	that	effective	haemostasis	was	achieved	in	67	(68%)	of	98	
patients;	31	(31%)	of	98	had	non-	effective	or	poor	haemostasis,	and	
for	two	patients	effective	haemostasis	could	not	be	assessed	primar-
ily	or	using	the	surrogate	efficacy	outcome	measurement	(Table	3).
Using	the	Sarode	criteria	for	haemostatic	efficacy,17 assessment was 
possible	in	66/100	patients.	In	34	(34%)	patients	the	rating	was	missing,	
mostly	due	to	the	absence	of	repeat	CT	scans	for	ICH.	Effective	haemo-
stasis	was	achieved	in	47	(71%)	of	66	evaluable	patients	(Table	3).
Stratification	by	type	of	bleeding	showed	that	in	nine	(22%)	of	41	
patients	with	an	ICH	the	haemostatic	efficacy	could	be	assessed	using	
the	Sarode	criteria,17	which	was	excellent	in	four	and	poor	in	five	pa-
tients.	Surrogate	efficacy	analyses	were	performed	for	patients	with	
ICH	without	haemostatic	efficacy	assessment	 (32	 [78%]).	Of	 the	32	
ICH	patients,	20	(63%)	were	classified	as	having	a	stable	neurological	
condition	 since	admission,	10	 (31%)	 as	 cessation	of	 further	medical	
treatment	due	to	poor	neurological	condition,	and	two	(6%)	as	no	re-
cords	available	(Table	3).
Total cohort N = 100 ICH N = 41 GI bleeds N = 36 Other bleeds N = 23
Dose	of	PCC	administered	in	IU
Males,	median	(IQR) 2000	(1500-	2250) 2000	(1750-	2500) 2000	(1500-	2250) 1750	(1125-	1750)
Females,	median	(IQR) 1500	(1000-	1750) 1500	(1250-	2000) 1250	(1000-	1500) 1250	(1000-	2000)
Dose	of	PCC	in	IU	per	kg,	median	(IQR)
Males 25	(20-	25) 25	(22-	26) 25	(28-	26) 23	(18-	26)
Females 22	(16-	28) 21	(12-	29) 22	(14-	29) 20	(10-	25)
Other	medical	treatment,	n	(%)
Vitamin	K 79	(79) 34	(83) 25	(69) 20	(87)
Tranexamic	acid 4	(4) 1	(2) 1	(3) 2	(9)
Administration	of	blood	products,	n	(%)
Red blood cells 45	(45) 2	(5) 28	(78) 15	(65)
Platelets 6	(6) 4	(10) 2	(6) 0
Fresh	frozen	plasma 8	(8) 1	(2) 5	(14) 2	(9)
Procedures	to	control	the	bleeding,	
n	(%)
39	(39) 12	(29) 21	(58) 6	(26)
Type	of	procedure,	n/N	(%)
Surgical 15/39	(38) 12/12	(100) 0 3/6	(50)
Endoscopic 21/39	(54) 0 20/21	(95) 1/6	(17)
Radiologic 3/39	(8) 0 1/21	(5) 2/6	(33)
GI,	gastrointestinal;	iCH,	intracranial	haemorrhage;	IQR,	interquartile	range;	IU,	international	units;	PCC,	prothrombin	complex	concentrate;	VKA,	vitamin	
K	antagonist.
TABLE  2 Treatment	of	VKA-	associated	bleeding	events
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In	the	36	patients	presenting	with	GI	bleeding,	20	(56%)	had	excel-
lent	haemostatic	efficacy,	nine	good,	six	poor	and	in	one	patient	the	
rating	was	not	assessable.
3.3.2 | INR correction
At	presentation,	the	median	INR	was	3.85	with	an	interquartile	range	
(IQR)	of	2.9-	5.8.	Data	on	INR	correction	after	receiving	PCC	was	not	
available	for	50	patients.	For	the	remaining	50	patients,	INR	correc-
tion	was	rapid;	1	hour	after	start	of	infusion,	35	(70%)	of	patients	had	
an	INR	≤1.4.	The	baseline	INR	of	the	patients	who	had	a	follow	up	INR	
was	a	median	3.8	with	an	IQR	of	2.7-	6.2.
For	patients	who	achieved	effective	haemostasis	(n	=	67),	the	
median	baseline	INR	was	4.4	(IQR	3.1-	6.6).	INR	after	PCC	admin-
istration	was	available	 for	61	 (94%)	patients	 and	was	≤1.4	 in	40	
of	61	 (66%)	within	 the	hour.	For	patients	with	poor	haemostatic	
outcome	 (n	=	31	 in	 total),	median	baseline	 INR	was	3.59	with	an	
IQR	of	2.7-	4.5.	For	23	(74%)	of	them	the	INR	was	available	after	
PCC	administration	and	the	INR	lowered	to	≤1.4	in	15	of	23	(65%)	
patients.
In	 patients	with	 ICH,	 the	median	 INR	 at	 presentation	was	 3.25	
(IQR	2.6-	5.1).	Data	on	INR	normalization	after	PCC	administration	was	
available	for	34	of	41	(83%)	ICH	patients	and	27	of	them	achieved	an	
INR	≤1.4	within	1	hour.
INR	measurement	at	24	hours	after	PCC	infusion	was	performed	
in	77	patients	and	the	median	INR	value	was	1.3	(IQR	1.1-	1.6).
3.3.3 | Safety outcomes
Thromboembolic	 complications	 were	 reported	 in	 5	 (5%)	 patients	
(Table	4).	 Four	 of	 these	 were	 venous	 thromboembolic	 events.	
Eleven	 (11%)	 patients	 had	 a	 new	 bleeding	 complication	 within	
30	days	 after	 the	 VKA	 associated	 bleeding	 event.	 Most	 of	 these	
were	re-	bleedings	at	the	same	location	as	the	initial	bleeding	event.
By	 day	 30	 after	 PCC	 administration,	 22	 (22%)	 deaths	 were	
observed	 (Table	4),	 of	 which	 18	 were	 in	 patients	 with	 ICH.	 The	
mortality	rate	in	ICH	patients	was	44%	(18	of	41)	and	in	patients	
with	GI	bleeding	8%	(3	of	36).	The	cause	of	death	was	related	to	
the	bleeding	event	in	13	(59%)	of	22	of	the	patients.	None	of	the	
deaths	were	attributed	to	thrombosis,	 ie,	pulmonary	embolism	or	
myocardial	 infarction.	 The	 median	 duration	 of	 hospital	 stay	 was	
7	days,	and	21%	of	patients	was	admitted	in	the	ICU	for	a	median	
of	3	days.
3.3.4 | Clinical presentation and course
Figure	1	details	the	results	of	the	classification	of	the	VKA-	associated	
major	 bleeding	 events	 at	 presentation	 (N	=	86).	 None	 of	 the	major	
bleeding	episodes	were	classified	as	category	1;	ie,	presenting	with-
out	any	clinical	emergency.	A	severe	clinical	presentation	(category	3	
or	4)	was	observed	in	64%	of	the	patients.	One	patient	presented	with	
a	 bleeding	 event	 that	was	 fatal	 before	 or	 almost	 immediately	 after	
entering	the	hospital	(category	4).
The	 clinical	 course	 of	 VKA-	associated	 major	 bleeding	 events	
treated	 with	 PCC	 was	 categorized	 as	 3	 or	 4	 in	 50%	 of	 patients	
(Figure	1).	Four	(5%)	major	bleeds	met	the	criteria	for	severest	clinical	
course	in	which	death	was	unavoidable	and	life-	saving	attempts	were	
not	undertaken	(category	4).
TABLE  3 Haemostatic	efficacy	of	VKA-	associated	bleeding	
events
Total patients N = 100
Adapted	assessment	of	haemostatic	efficacy,	n/N	(%)a
Effective	haemostasis 67/98	(68)
Poor	haemostasis 31/98	(32)
Missing	or	no	record 2/100	(2)
Secondary	outcomes
Haemostatic	efficacy	rating	by	category	according	to	Sarode,	n/N	(%)
Excellent 35/100	(35)
Good 12/100	(12)
Poor 19/100	(19)
Missing	primary	rating 34/100	(34)
Surrogate	haemostatic	efficacy,	n/N	(%)b
Effective	haemostasis 20/32	(63)
Non-	effective	or	poor	haemostasis 12/32	(37)
ICH,	intracranial	haemorrhage;	VKA,	vitamin	K	antagonist.
aCombined	haemostatic	efficacy	and	surrogate	efficacy.
bIn	patients	with	ICH.
TABLE  4 Safety	outcomes	of	VKA-	associated	bleeding	events
Total patients N = 100
Thromboembolic	complications	<30	days,	n	(%) 5	(5)
Type	of	complication,	n/N	(%)
Myocardial	infarction 1/5	(20)
Deep	vein	thrombosis	or	pulmonary	embolism 4/5	(80)
Bleeding	complications	<	30	days,	n	(%) 11	(11)
Type	of	complication,	n/N	(%)
Intracranial	bleeding 1/11	(9)
Gastro-	intestinal	bleeding 5/11	(46)
Other 4/11	(36)
Unknown 1/11	(9)
Mortality,	n	(%) 22	(22)
Cause	of	death,	n/N	(%)
Ischemic	stroke 1/22	(5)
Bleeding 13/22	(59)
Other 8/22	(36)
Length	of	hospital	stay	in	days,	median	(IQR) 7	(5-	13)
Admission	at	ICU,	n	(%) 21	(21)
Length	of	stay	in	ICU	in	days,	median	(IQR) 3	(1-	5)
ICU,	 intensive	care	unit;	 IQR,	 interquartile	range;	TIA,	transient	 ischemic	
attack;	VKA,	vitamin	K	antagonist.
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4  | DISCUSSION
The	present	multicenter	cohort	study	shows	that	infusion	of	PCC	was	
able	to	achieve	effective	haemostasis	 in	68%	of	patients	with	VKA-	
associated	bleeding	complications	based	on	an	adapted	assessment	of	
haemostatic	efficacy	using	our	surrogate	efficacy	outcome	for	ICH	pa-
tients.	In	addition,	TE	complication	rates	were	low	and	mortality	rates	
rather	high	within	30	days	after	PCC	administration.	Sub-	classification	
of	clinical	presentation	and	course	of	major	VKA-	associated	bleeding	
showed	that	two-	thirds	of	patients	had	a	severe	clinical	presentation,	
and	half	also	had	a	severe	clinical	course,	meaning	that	the	bleeding	
was	life-	threatening	and	required	elaborate	measures	to	avoid	death,	
could	still	be	fatal	after	interventions	and	could	lead	to	permanent	dis-
ability,	or	death	was	unavoidable.
In	 a	 previously	 published	 randomized	 controlled	 trial,	 PCC	was	
compared	to	plasma	for	immediate	reversal	of	VKA-	associated	major	
bleedings.17	In	that	study,	effective	haemostasis	was	achieved	in	72%	
of	patients	 receiving	PCC,	which	 is	 consistent	with	our	 findings.	An	
advantage	of	our	cohort	study	is	that	we	included	all	consecutive	pa-
tients	with	bleeding	events	in	comparison	to	trial	patients	that	had	to	
fulfill	in-	and	exclusion	criteria.17
The	 rapid	 and	 almost	 complete	 INR	 normalization	 observed	 in	
the	 current	 analysis	 is	 consistent	with	 findings	 from	 previous	 stud-
ies.3,17,24–27	In	addition,	the	reported	TE	event	rate	(5%)	is	comparable	
to	 those	 from	earlier	 reports	 (range	3.9-	6.2%).17,25,28,29	The	possible	
association	between	the	administration	of	PCC	and	the	occurrence	of	
TE	complications	remains	a	concern.	In	most	studies,	including	ours,	it	
is	impossible	to	disentangle	the	potentially	thromboembolic	effects	of	
PCC	from	the	effects	of	cessation	of	anticoagulation.27,29	Finally,	the	
observed	mortality	 rate	was	 22%.	This	 rate	was	 similar	 to	 numbers	
reported	(25%)	in	a	recent	systematic	review	of	PCC,25 but somewhat 
higher	than	in	other	studies	(range	5.8-	7.8%).17,30	The	high	mortality	
rate	 in	 this	 study	 can	be	explained	by	 the	 large	number	of	patients	
included	with	ICH	compared	to	other	studies,	reflecting	the	presence	
of	severe	bleeding	complications	of	VKA	treatment.
Strengths	 of	 the	 present	 study	 include	 consecutive	 sampling,	
the	 relative	 homogeneous	 population	 of	 patients	with	VKA-	related	
bleeding	events	 that	were	 all	 treated	with	PCC,	 the	 representative-
ness	of	the	patients	from	daily	practice,	the	comprehensive	and	stan-
dardized	data	 retrieval	on	standardized	report	 forms,	 the	use	of	 the	
extensive	predefined	criteria	for	haemostatic	efficacy,	the	evaluation	
of	clinically	relevant	outcome	parameters	(INR	normalization,	throm-
boembolic	complications,	and	mortality),	and	the	long-	term	availability	
and	experience	with	PCC	in	all	national	hospitals	in	the	Netherlands.
Some	methodological	 aspects	of	 our	 study	 require	 further	 com-
ment.	First,	no	repeat	CT	scan	after	reversal	with	PCC	was	performed	
in	almost	80%	of	patients	with	ICH.	This	is	explained	by	local	treatment	
protocols	 in	which	 repeat	CT	 imaging	 is	 only	 done	 in	 patients	with	
neurological	deterioration	and	not	in	patients	that	are	neurologically	
stable	or	in	patients	with	infaust	prognosis	who	are	considered	beyond	
repair.	We	believe	our	surrogate	outcome	to	be	a	valid	surrogate	for	
haemostatic	efficacy.	Haematoma	expansion	is	unlikely	and	arguably	
clinically	irrelevant	in	patients	without	neurological	deterioration	and	
vice	versa	a	poor	neurological	condition	might	be	indicative	of	an	in-
crease	in	haematoma	volume	partly	due	to	cessation	of	further	medi-
cal	treatment.	Second,	our	study	was	a	retrospective	cohort	study.	It	is	
therefore	not	possible	to	implicate	causal	relations	between	PCC	and	
clinical	study	outcome	parameters.	Due	to	the	observational	nature	of	
our	study	and	the	variable	follow-	up	data	available,	the	results	of	this	
study	can	be	particularly	used	for	hypothesis-	generating	purposes.	In	
addition,	one	should	be	careful	with	the	interpretation	of	the	results,	as	
there	may	be	a	selection	bias;	patients	that	have	a	very	poor	prognosis	
beforehand	will	not	be	treated	as	aggressively,	hence	there	may	be	a	
selection	of	patients	that	do	receive	PCC	based	on	a	better	prognosis	
at	presentation.	Furthermore,	all	centers	that	participated	in	this	study	
were	tertiary	university	medical	hospitals.	These	hospitals	usually	treat	
patients	with	the	very	worst	prognoses,	but	on	the	other	hand	do	have	
elaborate	treatment	options	and	interventions	available,	for	example	
neurosurgical	departments.	This	could	have	also	introduced	selection	
bias	leading	to	over-	or	underestimation	of	true	treatment	effects.	A	
third	limitation	is	that	we	did	not	include	a	control	group	of	patients	
receiving	 other	 treatment	 to	 restore	 haemostasis.	We	 are	 therefore	
not	able	to	compare	the	results	directly	with	other	treatment	options.	
Given	the	current	guidelines,	a	meaningful	comparison	with	no	hae-
mostatic	treatment	is	not	possible	from	observational	data.	Especially	
in	ICH,	where	retrospective	studies	are	hampered	by	the	absence	of	
repeat	 CT,	 prospective	 and	 possibly	 interventional	 data	 on	 efficacy	
are	needed.	Furthermore,	 this	 study	had	a	small	 sample	size	of	100	
patients	which	might	have	influenced	the	results;	possible	existing	dif-
ferences	 in	 treatment,	management	 or	 outcomes	between	different	
types	of	bleeding	may	not	have	been	detected.	Another	limitation	is	
that	data	on	INR	correction	were	not	available	for	50%	of	the	patients.	
Therefore,	 these	findings	need	to	be	 interpreted	with	caution,	since	
they	do	not	represent	the	total	study	population.	The	described	INR	
values	after	PCC	administration	might	be	an	over-	or	underrepresen-
tation	of	the	true	INR	values	for	all	patients.	Finally,	14%	of	patients	
were	classified	as	having	a	minor	bleeding.	The	decision	to	treat	with	
PCC	was	at	the	discretion	of	the	treating	physician,	and	the	diagnosis	
of	major	or	minor	bleeding	was	made	 in	 retrospect	by	chart	 review.	
However,	one	could	speculate	that	events	classified	as	minor	bleeding	
F IGURE  1 Clinical	presentation	and	clinical	course	of	major	
bleeding	episodes	(n	=	86)	on	vitamin	K	antagonists
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might	not	have	needed	PCC,	and	 including	these	events	could	have	
slightly	overestimated	the	haemostatic	efficacy	outcome.
Overall,	the	results	from	this	study	support	the	use	of	PCC	as	pri-
mary	treatment	for	VKA-	associated	bleeding	events	as	recommended	
by	recent	guidelines.1,11,12	Since	we	 included	real-	world	patients	ex-
periencing	bleeding	complications	of	VKA	treatment,	our	 results	are	
likely	 to	 be	 generalizable	 to	 other	 patients	 needing	 PCC	 for	 VKA-	
associated	bleeding.
In	conclusion,	our	study	assessed	clinical	outcomes,	haemostatic	
efficacy	and	INR	normalization	in	patients	treated	with	PCC	for	VKA-	
associated	 bleeding	 complications.	 The	 most	 frequently	 observed	
bleeding	was	 ICH.	PCC	administration	was	 shown	 to	achieve	effec-
tive	haemostasis	in	68%	of	patients	with	VKA-	associated	bleeding.	TE	
complication	rates	were	low,	but	mortality	rates	high,	due	to	the	large	
number	of	patients	presenting	with	ICH.
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